KeyBanc raised the firm’s price target on Encompass Health (EHC) to $122 from $120 and keeps an Overweight rating on the shares. The firm says Q1 results look very impressive and continue to support its positive long-term thesis. In KeyBanc’s view, the company’s consistent performance is underpinned by its successful de novo/JV strategy, growing demand for IRF services, and Encompass Health’s structural advantages vs. subscale nonprofit units. Additionally, the firm is optimistic the company will remain insulated from ongoing healthcare policy and macro uncertainty.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC:
- Encompass Health price target raised to $129 from $118 at Barclays
- Encompass Health: Strong Financial Performance and Resilient Growth Justify Buy Rating
- Encompass Health Appoints New COO Patrick W. Tuer
- Encompass Health names Patrick Tuer as COO, effective immediately
- Encompass Health reports Q1 adjusted EPS $1.37, consensus $1.19